No annual revenue total was found in ARTELO BIOSCIENCES, INC.'s SEC filings.
Artelo Biosciences, Inc. (ARTL) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $4.2 million in cash and investments and $49,000 in total debt.
Revenue
—
Net income (TTM)
$-12.67M
-20.6% vs year-ago TTM
Operating cash flow (TTM)
$-12.63M
-131.5% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-7.07
Dividend per share
None
Shares outstanding
2.12M
-35.2% vs prior year
Net cash
$4.15M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621221
- Former names
- REACTIVE MEDICAL INC. (until Apr 17, 2017); KNIGHT KNOX DEVELOPMENT CORP. (until Feb 6, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Aug 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$7.4M |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$7.4M |
| Diluted EPS | -$12.52 | -$18.30 | — | — | — |
| Operating cash flow | -$8.5M | -$8.3M | -$8.2M | -$8.0M | -$6.1M |
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $12.6M |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $593,000 |
| Stockholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $12.0M |
| Cash and investments | $600,000 | $0 | $15.2M | $25.2M | $10.1M |
| Total debt | $69,000 | $104,000 | $23,000 | $63,000 | $67,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 27, 2026 | Aug 26, 2026 |
| 10-Q/A | Amended quarterly report | Aug 20, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 17, 2026 | Jul 17, 2026 |
| ARS | Annual report to shareholders | Jun 5, 2026 | Dec 31, 2025 |
All 465 Artelo Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.